Composition, form of production and packaging
Long-acting tablets slightly convex on both sides, disk-shaped, white with a marble pattern, with a bitter taste, odorless; on the bend - white.
1 tab.
potassium chloride 1 g,
which corresponds to the content of K + 524.44 mg (13.3 mmol)
Auxiliary substances: silicon dioxide colloidal anhydrous (aerosil A200) - 10 mg, polyvinyl butyral (movital B30T) - 57.50 mg, cetyl alcohol - 17 mg, magnesium stearate - 1 mg, talc - 8 mg.
10 pieces. - blisters (3) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2011.
PHARMACHOLOGIC EFFECT
Potassium reduces excitability and conductance of the myocardium, weakens the toxic effect of cardiac glycosides, without affecting their positive inotropic effect.
In small doses, K + dilates the coronary vessels, in large - narrows. Participates in the process of carrying out nerve impulses. Activates many cytoplasmic enzymes, regulates intracellular osmotic pressure, protein synthesis, amino acid transport. Improves the contraction of skeletal muscles in muscular dystrophy, myasthenia gravis.
PHARMACOKINETICS
After oral administration, it is easily and practically in any amount passively absorbed (absorption - 70%), because its concentration (both food and released from the dosage form) is higher in the lumen of the small intestine than in the blood. Of the retard tablets, gradually and slowly released throughout the gastrointestinal tract. In the ileum and large intestine, K + is secreted into the lumen of the gut by the principle of conjugated metabolism with Na + and excreted with bile (10%). Distribution of K + in the body lasts about 8 hours from the time of admission. T 1/2 in the absorption phase - 1.31 h; release time from retard tablets - 6 h.
INDICATIONS
- prevention and treatment of hypokalemia of various genesis, incl. caused by various conditions and diseases (vomiting, diarrhea) and mediated drug therapy (diuretics, glucocorticosteroids, cardiac glycosides).
DOSING MODE
Inside. The dose is set individually depending on the disease and the concentration of potassium in the blood plasma. 1-2 g / day (based on potassium chloride), if necessary, increase the dose to 6 g / day.
SIDE EFFECT
From the gastrointestinal tract: nausea, vomiting, diarrhea, flatulence, abdominal pain, ulceration of the mucous membrane of the gastrointestinal tract, gastrointestinal bleeding, perforation and intestinal obstruction.
From the nervous system: paresthesia, muscle weakness, confusion.
From the cardiovascular system: lowering blood pressure, arrhythmia, heart block, cardiac arrest.
Other: hyperkalemia, allergic reactions.
CONTRAINDICATIONS
- Hyperkalemia;
- complete AV block;
- adrenal insufficiency;
- chronic renal failure;
- concomitant therapy with potassium-sparing diuretics;
- metabolic disorders (acidosis, hypovolemia with hyponatremia);
- erosive and ulcerative lesions of the gastrointestinal tract;
- Pregnancy;
- breast-feeding;
- age up to 18 years;
- Hypersensitivity to the drug.
PREGNANCY AND LACTATION
If necessary, use in pregnancy should be compared with the expected benefit for the mother and the potential risk to the fetus. For the duration of treatment, breastfeeding should be discontinued.
APPLICATION FOR FUNCTIONS OF THE LIVER
Contraindicated:
chronic renal failure.
APPLICATION FOR CHILDREN
Safety and effectiveness of potassium chloride in children have not been established.
SPECIAL INSTRUCTIONS
During the treatment it is necessary to control the K + content in the serum, ECG, CBS.
Safety and effectiveness of potassium chloride in children have not been established.
A diet with a high content of sodium chloride increases the excretion of K + from the body.
It should be borne in mind that hyperkalemia, leading to death, can develop rapidly and proceed asymptomatically.
OVERDOSE
Symptoms: hyperkalemia (muscle hypotension, paresthesia, AV-conduction delay, arrhythmias, cardiac arrest). Early clinical signs of hyperkalemia usually appear at a serum K + concentration of more than 6 meq / l: tapering of the T wave, broadening of the QRS complex.
More severe symptoms of hyperkalemia - muscle paralysis and cardiac arrest - develop at a concentration of K + 9-10 meq / L.
Treatment: inside or in / in - a solution of sodium chloride; if necessary, hemodialysis and peritoneal dialysis.
DRUG INTERACTION
Potassium-sparing diuretics, potassium preparations, ACE inhibitors, NSAIDs increase the risk of hyperkalemia.
Reduces the side effects of cardiac glycosides.
Strengthens the action of quinidine, the side effect of disopyramide.
TERMS OF RELEASE FROM PHARMACY
The drug is released by prescription.
TERMS AND CONDITIONS OF STORAGE
Store in a dry place at a temperature of 15-30 В° C. Keep out of the reach of children.
Shelf life - 3 years.
